Business Description
LungLife AI Inc
NAICS : 621512
SIC : 2835
ISIN : USU5500L1045
Description
LungLife AI Inc is focused on a developing clinical diagnostic solutions for lung cancer. The Company generates revenue from People's Republic of China and also has its presence in the United States of America.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 8.18 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.07 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -12.04 | |||||
Beneish M-Score | -2.13 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -45 | |||||
3-Year EBITDA Growth Rate | -12.8 | |||||
3-Year EPS without NRI Growth Rate | -8.9 | |||||
3-Year FCF Growth Rate | -23.4 | |||||
Future 3-5Y Total Revenue Growth Rate | 211.06 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 27.96 | |||||
9-Day RSI | 18.9 | |||||
14-Day RSI | 18.43 | |||||
6-1 Month Momentum % | -70.32 | |||||
12-1 Month Momentum % | -11.54 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.28 | |||||
Quick Ratio | 2.28 | |||||
Cash Ratio | 1.96 | |||||
Days Sales Outstanding | 1527.59 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | 4.58 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -12697.22 | |||||
Net Margin % | -11894.44 | |||||
FCF Margin % | -11166.67 | |||||
ROE % | -50.74 | |||||
ROA % | -43.62 | |||||
ROIC % | -77.72 | |||||
ROC (Joel Greenblatt) % | -1132.74 | |||||
ROCE % | -49.05 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 72.5 | |||||
PB Ratio | 0.59 | |||||
Price-to-Tangible-Book | 2.03 | |||||
EV-to-EBIT | -0.59 | |||||
EV-to-Forward-EBIT | -0.63 | |||||
EV-to-EBITDA | -0.62 | |||||
EV-to-Forward-EBITDA | -0.67 | |||||
EV-to-Revenue | 70.44 | |||||
EV-to-Forward-Revenue | 0.58 | |||||
EV-to-FCF | -0.63 | |||||
Price-to-Net-Current-Asset-Value | 2.7 | |||||
Price-to-Net-Cash | 4.05 | |||||
Earnings Yield (Greenblatt) % | -168.76 | |||||
FCF Yield % | -90.59 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
LungLife AI Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 0.042 | ||
EPS (TTM) (€) | -0.196 | ||
Beta | 0 | ||
Volatility % | 199.85 | ||
14-Day RSI | 18.43 | ||
14-Day ATR (€) | 0.008532 | ||
20-Day SMA (€) | 0.1689 | ||
12-1 Month Momentum % | -11.54 | ||
52-Week Range (€) | 0.157 - 1.56 | ||
Shares Outstanding (Mil) | 30.66 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
LungLife AI Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
LungLife AI Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
LungLife AI Inc Frequently Asked Questions
What is LungLife AI Inc(FRA:9H4)'s stock price today?
The current price of FRA:9H4 is €0.16. The 52 week high of FRA:9H4 is €1.56 and 52 week low is €0.16.
When is next earnings date of LungLife AI Inc(FRA:9H4)?
The next earnings date of LungLife AI Inc(FRA:9H4) is 2024-08-08 Est..
Does LungLife AI Inc(FRA:9H4) pay dividends? If so, how much?
LungLife AI Inc(FRA:9H4) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |